PEAK PROCESSING LIMITED — Regulatory Filings 2019

Jul 31, 2019

==> picture [136 x 82] intentionally omitted <==

ASX Announcement | 1 August 2019 Althea Group Holdings (ASX:AGH)

Althea exports first shipment of medicinal cannabis to the UK and supplies first UK patient

Investment Highlights:

• Althea exports first UK shipment of medicinal cannabis products and completes first Althea medicinal cannabis product sale in the UK

• The shipment follows Althea’s receipt of an Import Licence from the UK Home Office

• Multiple patients have now been scripted Althea medicinal cannabis in the UK, with a substantial pipeline of patients under assessment for further prescriptions

• Expanded partnership with Cannvalate Pty Ltd, opening a key additional channel in the UK

1 August 2019: Australian medicinal cannabis company Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) is pleased to announce that it has successfully exported its first shipment of Althea medicinal cannabis products into the United Kingdom (‘ UK ’).

First UK patient milestone achieved

In a major milestone, the first patient prescribed Althea’s medicinal cannabis in the UK received their medication on Wednesday 31 July 2019.

The shipment followed the Australian Government’s Office of Drug Control granting Althea an export permit for its medicinal cannabis products. Further shipments are planned in the coming weeks as the Company ramps up its UK operations.

Althea has clearly defined the prescription pathway for its products in the highly regulated UK market. This has resulted in multiple patients being scripted Althea medicinal cannabis in the UK, with a substantial pipeline of patients under assessment for further prescriptions.

The Company is replicating the highly successful strategy it has employed in the Australian market to simplify patient access to medicinal cannabis in the UK, where only a limited number of patients have ever accessed medicinal cannabis – usually on compassionate grounds. In Australia, Althea has now reached 1,445 patients.

Althea CEO Josh Fegan said: “Healthcare Professionals need a high degree of confidence in their ability to navigate regulations when considering whether to prescribe medicinal cannabis and the UK is no different. What makes Althea so special is our ability to work with prescribers to cut through the regulations so that they can prescribe Althea medicinal cannabis with absolute confidence and see the patient results for themselves. We now have the expertise to help commercialise cannabis-based medicines in the UK and that is ground-breaking.”

Althea Group Holdings Limited (ASX:AGH) ⋅ www.althea.life ACN 626 966 943 ⋅ Level 37, 360 Elizabeth Street, Melbourne 3000

1

Expansion of partnership with Cannvalate

To support its UK growth, Althea has also set up a key additional channel in the UK via a Services Agreement (‘ the agreement ’) with Cannvalate Pty Ltd (‘ Cannvalate ’).

Under the agreement, Cannvalate will serve as a non-exclusive provider of Althea’s medicinal cannabis products in the UK with the aim of rapidly increasing Althea’s network of existing prescribers, and ultimately, its patient base in the UK.

The agreement also marks the expansion of Althea’s partnership with Cannvalate, following their successful collaboration in the Australian market. Althea signed a product supply and distribution agreement with Cannvalate earlier this year, providing the Company with access to Cannvalate’s network of medicinal cannabis-prescribing clinics in Australia.

Strategic growth initiatives for UK continue

In parallel, the Company is currently engaged in a number of strategic growth initiatives targeting the UK including:

• Launch of Althea’s own chain of private medical clinics in the UK branded as ‘MyAccess Clinics’ with an intention to invest approximately A$1.5m in further expansion over the next two years:

  • Belgravia clinic opened in July 2019

  • Bristol clinic intended to begin assessing patients in the current quarter

  • Glasgow clinic intended to begin assessing patients in the current quarter

• Providing product, on commercial terms, for Drug Science’s ‘Project TWENTY21’, the UK’s first national pilot for medical cannabis which aims to enrol 20,000 patients by the end of 2021

Althea CEO Josh Fegan said: “Successfully shipping our first products to the UK is a major milestone for our global expansion plans. We are confident that we will able to replicate the highly successful strategy we have employed in the Australian market and are pleased to have expanded our partnership with Cannvalate. Our UK and European strategic initiatives continue to progress, and our Australian operations are maintaining strong growth.”

-ENDS-

For further information, please contact:

Media Enquiries

Althea

Josh Fegan Julia Maguire CEO & Managing Director The Capital Network M: 1300 70 20 20 M: +61 419 815 386 E: contact@althea.life E: julia@thecapitalnetwork.com.au

Australian Investors

PAC Partners Securities

M: 03 9114 7401

• E: enquiries@pacpartners.com.au

Althea Group Holdings Limited (ASX:AGH) ⋅ www.althea.life ACN 626 966 943 ⋅ Level 37, 360 Elizabeth Street, Melbourne 3000

2

Althea Group Holdings Limited (ASX:AGH)

Althea is an Australian licensed producer, supplier and exporter of pharmaceutical grade medicinal cannabis and is listed publicly on the Australian Securities Exchange (ASX:AGH). Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.

Althea currently operates within highly regulated medicinal cannabis markets including Australia and the United Kingdom, with plans to expand into emerging markets throughout Asia and Europe.

To learn more, please visit: www.althea.life

Althea Group Holdings Limited (ASX:AGH) ⋅ www.althea.life ACN 626 966 943 ⋅ Level 37, 360 Elizabeth Street, Melbourne 3000

3